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The world-wide obesity epidemic constitutes a severe threat to human health and wellbe-
ing and poses a major challenge to health-care systems. Current therapeutic approaches,
relying mainly on reduced energy intake and/or increased exercise energy expenditure,
are generally of limited effectiveness. Previously believed to be present only in children,
the existence of metabolically active brown adipose tissue (BAT) was recently demon-
strated also in healthy human adults. The physiological role of BAT is to dissipate chemical
energy, mainly from fatty acids, as heat to maintain body temperature in cold environments.
Recent studies indicate that the activity of BAT is negatively correlated with overweight and
obesity, ﬁndings that raise the exciting possibility of new and effective weight reduction
therapies based on increased BAT energy expenditure, a process likely to be amenable to
pharmacological intervention.
Keywords: brown adipose tissue, thermogenesis, energy expenditure, obesity, overweight, weight loss, metabolic
syndrome
INTRODUCTION
The prevalence of overweight and obesity has increased world-
wide during the recent decades, constituting a severe threat to
public health and causing enormous health-care costs. Obesity is
a major risk factor for type II diabetes mellitus, cardiovascular
disease, osteoarthritis, and certain forms of cancer (Haslam and
James, 2005), ultimately leading to increased mortality (Pischon
et al., 2008; Berrington De Gonzalez et al., 2010; Zheng et al.,
2011). The causes of obesity are complex in terms of physiology,
but are quite straightforward in terms of physics: obesity stems
from a long-term imbalance of energy intake and energy expen-
diture. While lipid deposition in adipose tissue is a normal and
vital physiologic process not necessarily causing disease, excess
triglyceride accumulation strains the capacity of adipose depots
and often leads to ectopic lipid deposition in skeletal muscle and
liver. This perturbs amultitude of metabolic pathways,which leads
to insulin resistance and type II diabetes mellitus (Qatanani and
Lazar, 2007).
Fortunately, the adverse metabolic consequences of obesity can
be reversed by weight loss (Petersen et al., 2005). However, this is
often difﬁcult to achieve with currently available therapies.
LIMITATIONS OF CURRENT THERAPIES AGAINST OBESITY
Presently, the only scientiﬁcally proven,effective therapyof morbid
obesity, both in terms of weight loss and decreased morbidity and
mortality, is bariatric surgery (Sjostrom et al., 2004, 2007; Adams
Abbreviations: BAT, brown adipose tissue; BMR, basal metabolic rate; DIO2, type 2
deiodinase; FDG PET–CT, 18F-ﬂuorodeoxyglucose positron emission tomography
combined with computed tomography; FGF, ﬁbroblast growth factor; SNS, sympa-
thetic nervous system; THR, thyroid hormone receptor; UCP1, uncoupling protein
1; WAT, white adipose tissue.
et al., 2007). However, this therapeutic approach is invasive and it
is available only to a subgroup of morbidly obese subjects.
A mainstay of current medical management of overweight and
obesity is caloric restriction, i.e., limiting the amount of calories
ingested to a level below the patient’s estimated or measured total
energy expenditure (Eckel, 2008). While this may seem to be the
most logical approach, it faces several obstacles: the sensation of
hunger is recognized as very unpleasant and drugs acting on the
CNS to suppress appetite such as Sibutramine or Rimonabant
can cause serious adverse events. Use of sibutramine, a substance
targeting the central monoamine system, was associated with
increased incidence of non-fatal myocardial infarction and stroke
(James et al., 2010), which led to its withdrawal. Another promis-
ing appetite suppressant, Rimonabant, a cannabinoid receptor 1
blocker that was effective in inducing and maintaining weight loss
as well as improving insulin sensitivity, failed to get approval from
the Federal Drug Administration in the United States and was
withdrawn in Europe due to increased incidence of depression
and suicide (Christensen et al., 2007).
Additionally, caloric restriction as the sole method of weight
reduction is accompanied by both metabolic and behavioral com-
pensations leading to reduced basal metabolic rate (BMR) and
reduced physical activity level (Martin et al., 2007). These adapta-
tions commonly lead to unwanted weight regain, often predomi-
nantly as fat mass, once the caloric restriction ends (Dulloo et al.,
1997).
In comparison these compensatory changes were not observed
in a combination therapy of caloric restriction and exercise (Red-
man et al., 2009). This is in line with results from other studies,
identifying energy expenditure through physical activity as a main
determinant of successful weight reduction and long-term weight
control (Wing and Hill, 2001; Weinsier et al., 2002). Moreover, a
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combination of caloric restriction and structured exercise led to
greater weight loss and a more favorable cardio-metabolic proﬁle
(Goodpaster et al., 2010). Unfortunately, increasing physical activ-
ity often proves difﬁcult for obese patients due to musculoskeletal
and cardiovascular disease, causing a vicious circle of reduced exer-
cise, reduced energy expenditure, increased body weight and even
further reduced activity.Alternativeways to increase energy expen-
diture could expand the therapeutic options for treating obese
patients and ultimately lead to more successful treatment.
BROWN ADIPOSE TISSUE
BROWN ADIPOSE TISSUE PHYSIOLOGY
Adipose tissue exists in two distinct forms: white adipose tissue
(WAT) and brown adipose tissue (BAT). WAT is the main energy
storage compartment of the mammalian body. It is characterized
by adipocytes containing a single large lipid droplet storing excess
energy in the form of triglycerides. White adipocytes possess rel-
atively few mitochondria and a peripherally located nucleus. In
addition, WAT constitutes a large endocrine organ that secretes
hormones such as leptin and adiponectin which are involved in
the regulation of satiety and insulin sensitivity (Kershaw and Flier,
2004). BAT is a densely innervated and highly perfused tissue con-
sisting of brown adipocytes, a cell type characterized by small
multilocular lipids droplets, a central nucleus, and a high number
of mitochondria. The major differences between WAT and BAT
are summarized in Table 1.
Within the mitochondrial matrix acetyl-CoA derived from car-
bohydrates, fatty acids, or proteins is fed into the citric acid cycle.
The chemical energy released by the stepwise oxidation of acetyl-
CoA is then transferred to the electron transport chain in the inner
mitochondrial membrane building up a proton gradient across
the membrane. Usually, the ﬂow of protons back to the mito-
chondrial matrix through a channel in the ATP-synthase complex
powers the synthesis of ATP (Berg et al., 2007), thereby cou-
pling the oxidation of nutrients to the generation of the cell’s
energy currency. Brown adipocytes are unique in their expression
of UCP1, the gene encoding uncoupling protein 1. Activation of
UCP1 short-circuits or uncouples the proton gradient from ATP
generation, thereby dissipating the energy stored in the gradient
as heat (Figure 1A).
Table 1 | Characteristic of white vs. brown adipose tissue.
White adipose tissue Brown adipose tissue
White adipocytes contain
single large lipid droplet, few
mitochondria
Brown adipocytes contain multiple small
lipid droplets, rich in mitochondria
Secretes adipose derived
hormones, that regulate
insulin sensitivity and satiety
Densely vascularized and innervated by
sympathetic nerve endings
Stores excess energy as
triglycerides, releases fatty
acids during fasting periods
Expression of uncoupling protein 1
Dissipates chemical energy (mainly from
fatty acids) to generate heat
The physiological function of BAT is thus to convert chemical
energy, mainly from lipids, into thermal energy. This capability is
very important for small and hibernating mammals as well as for
newborn humans to maintain body temperature in cold environ-
ments. In the mammalian body heat is generated as a by-product
of basic cellular and organ functions (BMR), of digestion and
absorption of food, and of voluntary and involuntary movement.
If this amount of thermal energy does not sufﬁce to keep the body
temperaturewithin the normal range in a cold environment,adap-
tive thermogenesis sets in. Evenbefore core body temperature drops
cold is sensed by receptors in the skin. The afferent information
is integrated in the hypothalamus leading to disinhibition of its
thermogenesis-promoting neurons, which in turn increases sym-
pathetic output to BAT (Nakamura and Morrison, 2007). Acute
cold stress in non-cold adapted animals causes muscle shivering
as a ﬁrst mechanism to defend body temperature. During chronic
cold exposure the amount of shivering abates over the course of
days to weeks as non-shivering thermogenesis increases (Cannon
and Nedergaard, 2004). The signal from the sympathetic nervous
system (SNS) is relayed by noradrenergic neurons,which stimulate
G-protein coupled β3-adrenoreceptors (β3-AR) in BAT. Stimula-
tion of β3-ARs leads to lipolysis via activation of the Gs-adenylyl
cyclase-PKA pathway. The fatty acids released by lipolysis do not
only represent the main substrate of thermogenesis, but they also
activate UCP1 allosterically (Figure 1B; Cannon and Nedergaard,
2004).
Thyroid hormone is an important endocrine modulator of
thermogenesis. It potentiates the actions of catecholamines on
the β3-AR and adenylyl cyclase and increases the transcription
of UCP1 through thyroid hormone receptor (THR) response ele-
ments located in the UCP1 promoter (Silva and Rabelo, 1997).
Moreover, BAT expresses high levels of type 2 iodothyronine deio-
dinase (DIO2), an enzyme converting tetraiodothyronine (T4)
into the active triiodothyronine (T3). Type 1 iodothyronine deio-
dinase (DIO1) is mainly expressed in liver and kidney and is the
main source of plasma T3 in hyperthyroid patients. While DIO1
is under tight transcriptional control of thyroid hormones, DIO2
expression is induced by catecholamines acting through the cAMP
signaling cascade. Its effects in promoting T3 production are lim-
ited to BAT and do not affect plasma T3 levels (Bianco and Kim,
2006).
About 30 years ago Rothwell and Stock described that ad libi-
tum feeding of a high calorie diet rich in fat and carbohydrates,
casually dubbed “cafeteria diet,” led to recruitment and activa-
tion of BAT in rats and thus increased energy expenditure. They
concluded that BAT was a major site of diet induced thermoge-
nesis (DIT), the increase in energy expenditure that follows food
intake and might thus protect against diet induced obesity (Roth-
well and Stock, 1979). In contrast to cold-induced thermogenesis,
which is generally undisputed, the proposal of DIT as a function of
BAT ismore controversial (Kozak,2010; FrommeandKlingenspor,
2011).
ORIGINS AND DIFFERENTIATION OF BROWN ADIPOSE TISSUE
In contrast to earlier assumptions of a common origin of brown
and white adipocytes, recent research clearly demonstrates that
brown and white adipocytes have distinct developmental origins.
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FIGURE 1 | (A) Outline of UCP1 action in brown adipocyte mitochondria. The
electron transport chain generates a proton gradient across the inner
mitochondrial membrane. This electromotive force is usually drives
ATP-synthase restoring the cell’s energy currency ATP. Activation of UCP1 by
fatty acids in brown adipocytes dissipates the proton gradient without
coupling to ATP regeneration releasing the energy as heat. (Details of the
electron transport chain have been omitted for reasons of simplicity). (B)
Outline of BAT regulation. Upon cold exposure afferent signals from cold
receptors are integrated in the hypothalamus. The efferent signal is
transmitted via the sympathetic nervous system (SNS) and norepinephrine
(NE) acting on the β3-adrenoreceptor located on the brown adipocyte surface,
which is coupled to the cAMP second messenger pathway. Phosphorylation
of hormone sensitive lipase and perilipin activates lipolysis. The resulting free
fatty acids provide the fuel for thermogenesis and activate UCP1 allosterically.
Additionally, transcription of UCP1 and PGC-1α is activated via the CREB/CRE
pathway.
Atit et al. (2006) proposed a common origin of skeletal muscle and
BAT, based on their ﬁnding that speciﬁc cells of the dermomy-
otome positive for the transcription factor engrailed-1 develop
into both skeletal myocytes and brown, but not white adipocytes.
In parallel with this ﬁnding, lineage tracing revealed that both
brown adipocytes located in the interscapular BAT and myocytes
derive from precursors positive for the myogenic transcription
factor Myf5 (Timmons et al., 2007).
Seale et al. (2008) delineated the existence of two different
types of brown adipocytes: those found in “classic” BAT (e.g.,
interscapular BAT), deriving from Myf5 positive precursors, and a
second population,deriving from Myf5 negative precursors, that is
interspersed in WAT. Because these interspersed brown adipocytes
appear upon stimulation with cold or β3-AR agonists, we chose
to call them “recruitable” brown adipocytes to discriminate them
from the invariably present “classic” brown adipocytes, which are
located in typical BAT fat pads.
Our knowledge of BAT development and differentiation has
advanced considerably during recent years, as several transcrip-
tional regulators essential to BAT have been discovered.
PPARγ coactivator-1α (PGC-1α) is highly induced in BAT
upon cold exposure,mediated via SNS stimulation and the cAMP-
PKA second messenger pathway. It interacts with PPARγ and is
an important regulator of mitochondrial biogenesis and oxida-
tive phosphorylation. Ectopic overexpression of PGC-1α in white
adipocytes induces UCP1 and other thermogenic genes, while its
genetic ablation severely reduces the animals’ capacity for adaptive
thermogenesis (Seale et al., 2009). The importance of the cAMP-
PKA pathway for brown adipocyte development is highlighted by
the fact that FOXC2, a member of the forkhead transcription fac-
tor family, sensitized adipocytes to the actions of β3-AR agonists
by inducing the expression of the RIα subunit of PKA (Cederberg
et al., 2001; Dahle et al., 2002). Overexpression of FOXC2 in adi-
pose tissue led to a “browning” of white fat pads and protected
mice against diet induced obesity and insulin resistance.
In conjunction with the discovery of a common lineage of BAT
and muscle PRDM16 was identiﬁed as a molecular switch between
brown adipocyte and myocyte development. Ectopic expression
of PRDM16 in myoblasts induced differentiation into brown
adipocytes possessing the full molecular machinery necessary for
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thermogenesis. In contrast, loss of PRDM16 in BAT pre-cursor
cells led to a loss of the brown adipocyte phenotype and myocyte
differentiation (Seale et al., 2008). When PRDM16 was transgeni-
cally expressed in the subcutaneousWATof mice,brown adipocyte
like cells appeared in this fat pad, rendering the mice less obesity
prone and more glucose tolerant (Seale et al., 2011).
IMPLICATIONS OF BAT IN METABOLISM AND BODY WEIGHT IN
RODENTS
During the last three decades the effects of active BAT on body
weight and metabolism in rodents have been carefully studied.
Several different models of BAT disruption clearly demon-
strated its importance for adaptive thermogenesis and also high-
lighted its relevance for body weight regulation. Surgical dener-
vation or excision of BAT in mice led to increased body weight
as compared with sham operated animals (Dulloo and Miller,
1984). Biochemical disruption of BAT by expression of cholera
toxin A under the control of the UCP1 promoter induced obe-
sity and insulin resistance in mice (Lowell et al., 1993). A com-
plete knock-out of the UCP1 gene did, somewhat unexpectedly,
not result in obesity, when mice were housed at usual animal
facility temperatures (i.e., around 22˚C; Enerback et al., 1997).
However, keeping them at conditions of thermoneutrality (i.e.,
30–33˚C for mice) rendered the animals obese (Feldmann et al.,
2009).
Expansion of BATon the other hand resulted in opposite effects
on body weight and metabolism. Transgenic mice overexpressing
UCP1 in WAT displayed a reduced amount of subcutaneous fat at
3 months of age and when the transgene was expressed in a genet-
ically obese mouse strain, it protected against obesity (Kopecky
et al., 1995). Overexpression of the forkhead transcription factor
FOXC2 in adipose tissue led to a “browning” of WAT fat pads,
with expression of UCP1 and increased vascularization. Accord-
ingly, the animals were protected from diet induced obesity, as well
as insulin resistance and hypertriglyceridemia (Cederberg et al.,
2001; Kim et al., 2005).
Pharmacological stimulation of the β3-adrenoreceptor (β3-
AR) with the speciﬁc agonist CL316,243 in Zucker fa/fa rats led
to the appearance of brown adipocytes in WAT regions, increased
BMR, and reversed diet induced obesity. Upon treatment with the
agonist obese rats showed a more pronounced increase of BMR
than lean controls and partial reversion of hyperphagia, while
food intake remained constant in lean controls. Additionally, the
hyperinsulinemia and hyperglycemia of the Zucker fa/fa rats was
ameliorated, indicating reduced insulin resistance (Ghorbani and
Himms-Hagen, 1997).
Similar experiments were performed in mice. However, the
ability of β3-AR agonists to induce brown adipocytes in WAT
regions varied enormously between different mouse strains, as did
the body weight after high fat feeding. Importantly, the variation
of UCP1 expression in the classic interscapular BAT fat pad was
rather small between the different mouse strains, indicating that
the differences in bodyweightwere largely conferred by recruitable
brownadipocytes inWATregions (Collins et al.,1997;Guerra et al.,
1998). This genetic variability of UCP1 expression in different adi-
pose tissue compartments could not be explained by variation in
the expression of speciﬁc transcription factors, but rather suggests
different developmental mechanisms for the two brown adipocyte
populations (Xue et al., 2007).
Bartelt et al. investigated the implications of BAT activa-
tion on lipid metabolism. They demonstrated that clearance
of triglyceride-rich lipoproteins from plasma in BAT drastically
increased upon short-term cold exposure thus correcting hyper-
lipidemia and ameliorating insulin resistance inmice (Bartelt et al.,
2011). As hyperlipidemia is a leading risk factor for cardiovascular
disease, the authors speculated that activation of BAT might be
a valuable therapeutic approach to correct hypertriglyceridemia
and associated diseases in humans.
In conclusion, in rodents an impressive amount of scientiﬁc
evidence highlights the beneﬁcial consequences of active BAT for
regulation of normal body weight, insulin sensitivity, and lipid
metabolism. Given the implications of these ﬁndings, BAT had
already been considered an attractive therapeutic target in humans
suffering from overweight and obesity decades ago. However, the
recent proof of its presence and activity in human adults has
sparked new interest in this possibility.
BROWN ADIPOSE TISSUE IN HUMANS
EVIDENCE AND PREVALENCE OF ACTIVE BAT IN HUMAN ADULTS
While the existence of BAT in rodents and human infants has been
known for decades and its physiological function was described
as early as the 1960s, it was only recently that several researchers
could unequivocally identify active BAT in human adults using
18F-ﬂuorodeoxyglucose positron emission tomography combined
with computed tomography (FDG PET–CT; Cypess et al., 2009;
Van Marken Lichtenbelt et al., 2009; Virtanen et al., 2009). For
a summary of recent studies investigating BAT in humans see
Table 2.
The FDG PET–CT is currently the only imaging technique that
can visualize active BAT. Due to the ionizing radiation associated
with its use, it has up to now not been possible to conduct large
studies in healthy individuals to test for the presence of active BAT.
Instead researchers have often made use of already available FDG
PET–CT scans,most commonly obtained during routine diagnos-
tic studies for staging of cancer. The total proportion of subjects
displaying active BAT in these studies was relatively low, generally
below 10% (Cypess et al., 2009; Jacene et al., 2011; Ouellet et al.,
2011).
Using BAT as a therapeutic target to combat obesity and asso-
ciated diseases does, however, only make sense, if it is present in
the vast majority of patients and not just an occasional remnant of
BAT present at birth.While the data obtained from cross-sectional
retrospective analysis of FDG PET–CT scans performed for other
diagnostic purposes suggests that BAT is present only in aminority
of adults the true prevalence is probably signiﬁcantly higher.
The activity of BAT is highly variable and, among other fac-
tors, dependent on outdoor temperature at the time of diagnostic
imaging (Cypess et al., 2009; Saito et al., 2009; Ouellet et al.,
2011). Moreover, radiologists had noted bilateral symmetric glu-
cose uptake in FDG PET scans since the early 1990s. As, under-
standably, such“artifacts” interferedwith themain intention of the
diagnostic studies (predominantly detection of tumor and metas-
tases), they tried to suppress this unwanted PET tracer uptake by
using pre-medication with beta blockers, benzodiazepines and by
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Table 2 | Recent studies on BAT in humans, sorted by study type.
Reference Study population, characteristics Main findings
RETROSPECTIVEANALYSIS OF FDG PET–CT SCANS PERFORMED FOR ROUTINE DIAGNOSTIC STUDIES IN PATIENTS
Cypess et al.
(2009)
1972 Patients (3640 consecutive scans) FDG PET positive BAT in 76 of 1013 women (7.5%) and 30 of 959 men
(3.1%), inverse correlation of BAT activity with age, beta-blocker use,
and BMI among older patients.
Jacene et al.
(2011)
908 Patients; 445 female, 463 male; mean age±SD
58±15 years
FDG PET positive BAT in 56 of 908 patients (6.2%), patients without
active BAT had higher risk for hyperglycemia in univariate analysis.
Lee et al.
(2010)
2934 Patients; female 1848, male 1086; mean age 36 years;
age range 18–87 years
Active BAT identiﬁed in 250 patients (8.5%); 145 patients scanned
more than once, showing a high intra-individual variability of BAT
activity.
Active BAT associated with female sex. Inversely associated with age,
BMI, and fasting glucose.
Pfannenberg
et al. (2010)
3604 Patients screened, 260 patients analyzed; 98 BAT
positive, 162 study-date matched control subjects; 136
female, 124 male; mean age±SE, 48±1 years; age range
11–82 years; mean BMI 24.5±0.3 kg/m2
BAT activity was associated with female sex; inverse correlation of
BAT activity with age in men but not in women; inverse correlation
with BMI.
Gilsanz et al.
(2011)
71 Children and adolescents; 26 female, 45 male; age range
6–20 years
30 of 71 children displayed active BAT (42%); prevalence of active BAT
was positively correlated with muscle volume. No differences in age,
BMI, or sex were detected.
Ouellet et al.
(2011)
4842 Patients; 2370 female, 2472 male; mean age±SE,
62±0.2 years; age range 2–94 years
328 of 4842 patients with active BAT. Prevalence of active BAT was
negatively associated with BMI, diabetes mellitus, outdoor temper-
ature, and BMI. Men were less likely than women to display active
BAT.
Yilmaz et al.
(2011)
3666 Consecutive scans in 1832 patients screened; 30
patients positive for BAT, 90 age and sex matched controls
30 of 1832 patients (10 male, 20 female) displayed active BAT (preva-
lence 2%); non-alcoholic fatty liver disease was signiﬁcantly more
prevalent among patients negative for active BAT.
PROSPECTIVE STUDIES USING FDG PET–CTAND COLD EXPOSURE PROTOCOLS IN HEALTHYVOLUNTEERS
Saito et al.
(2009)
56 Healthy volunteers; 25 female, 31 male; 23–65 years of
age
Upon cold exposure active BAT was observed in 17 of 32 sub-
jects aged 23–35 years and in 2 of 24 subjects aged 38–65 years.
Inverse correlation of BAT activity vs. BMI, total and visceral body fat,
respectively.
Virtanen et al.
(2009)
5 Healthy volunteers, 20–50 years of age; PET–CT guided
surgical biopsies of adipose tissue taken in cervical region of
3 subjects
Cold exposure induced FDGuptake in all ﬁve subjects; presence of BAT
proven by immunohistochemistry and molecular analysis (qRT-PCR) for
BAT markers.
Van Marken
Lichtenbelt
et al. (2009)
24 Healthy volunteers; age range 20–32 years, male,
BMI<25 in 10 subjects, BMI>25 in 14 subjects; energy
expenditure measured at thermoneutrality and during cold
exposure
BAT activity observed in 23 of 24 subjects (96%) after cold exposure,
but not under conditions of thermoneutrality. BAT activity negatively
correlated with BMI and percentage body fat and positively correlated
with basal metabolic rate.
Vijgen et al.
(2011)
15 Morbidly obese subjects, 2 male, 13 female, BMI
35–48 kg/m2
Cold-induced BAT activity detected in 3 out of 15 morbidly obese
subjects.
Yoneshiro et al.
(2011)
162 Healthy volunteers; 59 female, 103 male; mean
age±SD 32.0±12.1; BMI 22.1±3.0 kg/m2
Cold activated BAT detected in 41% of subjects; inverse correlation of
active BAT with BMI, body fat content, abdominal fat, and age.
ANALYSIS OFTISSUE SAMPLES OBTAINED DURING SURGERY INTHE NECK REGION
Zingaretti et al.
(2009)
35 Patients; 8 male, 27 female; age range 18–82 years, BMI
range 18–37 kg/m2; thyroid surgery for goiter and papillary
carcinoma
Histologic evidence of BAT in 10 of 35 patients; presence of BAT
inversely correlated with BMI and age.
Lee et al.
(2011b)
Prospective cohort study in 17 patients; underwent
preoperative FDG PET/CT for staging of head and
neck-malignancies prior to surgery; analysis of BAT markers
in cervical fat biopsies compared to subcutaneous WAT
FDG PET/CT positive for BAT in 3 of the 17 patients. However, mole-
cular markers of BAT could be detected in cervical fat biopsies from
both PET positive and PET negative patients.
OTHER STUDIES
Wang et al.
(2011)
FDG PET/CT in 14 patients with pheochromocytoma; 14
matched healthy controls
BAT activity as assessed by FDG PET correlated with total plasma
metanephrine.
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warming up to a comfortable room temperature before injecting
the tracer substance (Christensen et al., 2006; Soderlund et al.,
2007).
Studies speciﬁcally designed to detect BAT indicate a much
higher prevalence in adult humans. Van Marken Lichtenbelt et al.
(2009) used a speciﬁc cold stimulation protocol prior to FDG
PET scanning and were able to detect active BAT in 23 out of
24 healthy male subjects (96%). Using a different approach Lee
et al. examined 17 patients that underwent staging for head and
neck malignancy. While only 3 of 17 had indications of BAT in
the FDG PET–CT scan molecular analysis of samples taken from
the supraclavicular fat revealed the presence of molecular mark-
ers of BAT (UCP1, PRDM16) in all subjects (Lee et al., 2011b).
Of the 2934 patients examined with FDG PET–CT in a large Aus-
tralian study 145 were scanned more than once. The probability to
identify active BAT in an individual increased considerably with
the number of scans, allowing the authors to estimate the true
prevalence of BAT in their cohort to be 64% (Lee et al., 2010).
ASSOCIATION OF ACTIVE BAT AND OBESITY IN HUMANS
While the body of evidence is far frombeing as robust as in rodents,
several studies also link the activity of BAT in humans to obesity
and associated diseases.
Studies using retrospective analysis of routine FDG PET–CT
scans identiﬁed a negative correlation of BAT activity and body
mass index (BMI) in humans (Cypess et al., 2009; Lee et al., 2010;
Pfannenberg et al., 2010; Ouellet et al., 2011). The results of these
publications are corroborated by two trials in healthy volunteers
that underwent FDGPET–CT scanning after cold exposure to acti-
vate BAT (Saito et al., 2009; Van Marken Lichtenbelt et al., 2009).
Zingaretti et al. (2009) observed similar results when studying the
presenceof brownadipocytes in samples of adipose tissue collected
in the cervical region of 35 patients undergoing thyroid surgery.
Remarkably, active BAT was present in only 3 out of 15 morbidly
obese subjects (mean BMI 42.1 kg/m2) upon cold stimulation as
assessed with FDG PET–CT (Vijgen et al., 2011). However, the
presence of active BAT in 20% of the subjects indicates that BAT
activation might be a possible therapeutic intervention in at least
a part of morbidly obese patients.
The prevalence of PET positive BAT seems to decrease with
age, as assessed both in retrospective observational studies (Cypess
et al., 2009; Pfannenberg et al., 2010; Ouellet et al., 2011) and
in prospective studies in healthy volunteers (Saito et al., 2009;
Yoneshiro et al., 2011). The declining presence of active BAT with
age might be one explanation for the increase of overweight and
obesity with age.
In retrospective PET studies the prevalence and activity of BAT
was unanimously higher in women than in men (Cypess et al.,
2009; Ouellet et al., 2011). Evaluating the FDG PET–CT scans of
260 subjects, 98 of which displayed active BAT, Pfannenberg et al.
(2010) described that while in male subjects BAT activity and mass
declined with age, this was not the case in female subjects.
Although there are currently no studies prospectively address-
ing the question, whether active BAT might protect against insulin
resistance and diabetes, there is indirect evidence from retro-
spective cross-sectional studies of patients that underwent FDG
PET–CT. Using routine scans Jacene et al. (2011) investigated,
whether the presence of active BAT was predictive of elevated
fasting glucose levels at the time of the examination. Of the 908
patients 6.2% had FDG uptake in BAT and in the univariate analy-
sis patients without active BAT had a signiﬁcantly increased risk to
have a blood glucose level of more than 100 mg/dl (>5.6 mmol/l).
After adjusting for age, BMI, and sex this difference was not statis-
tically signiﬁcant. In a larger Australian cohort with 2934 patients,
250 of which displayed active BAT in FDG PET–CT, a signiﬁcant
correlation between fasting glucose andBAT activitywas observed.
The authors also analyzed data from patients who had been stud-
ied repeatedly at different time points and observed an inverse
correlation of blood glucose levels and BAT activity in this subset
(Lee et al., 2010). These ﬁndings are in line with another study
describing a reduced prevalence of active BAT in patients with
known diabetes (Ouellet et al., 2011).
Non-alcoholic fatty liver disease (NAFLD) is a manifestation
of the metabolic syndrome with ectopic lipid deposition in the
liver. It is often associated with insulin resistance or type II dia-
betes mellitus, hyperlipidemia, and hypertension (Vuppalanchi
and Chalasani, 2009). In another retrospective evaluation of FDG
PET–CT data the presence of active BAT in adults was indepen-
dently associated with a lower likelihood of NAFLD (Yilmaz et al.,
2011).
Recently, Gilsanz et al. published results of a retrospective
analysis of FDG PET–CT scans performed in 71 children and ado-
lescents. As expected, the overall prevalence of active BAT was
higher (42%) than in an adult population. Intriguingly, an asso-
ciation of BAT activity and muscle mass was observed. Contrary
to studies performed in adults, no associations with age, BMI,
or adiposity could be detected (Gilsanz et al., 2011). However, a
major limitation of this study is – as with most of the studies
using FDG PET–CT in adult humans – the fact that the study
population consisted only of subjects suffering from neoplastic
disease.
In some adult patients suffering from pheochromocytoma, a
catecholamine secreting tumor of the adrenal medulla, BAT had
been discovered and characterized ultrastructurally and biochem-
ically already in the 1980s (Ricquier et al., 1982). It was specu-
lated that the weight loss seen in many patients suffering from
pheochromocytoma was due to the activation or recruitment of
BAT through high levels of catecholamines (Lean et al., 1986). Not
unexpectedly, a more recent study was able to describe a signiﬁ-
cant correlation of plasma catecholamine levels and BAT activity
in patients with pheochromocytoma (Wang et al., 2011).
Correspondingly, the use of beta blockers was inversely cor-
related to the presence of active BAT in a retrospective, cross-
sectional study with FDG PET–CT (Cypess et al., 2009). In a
controlled prospective trial using cold exposure to activate adap-
tive thermogenesis, however, administration of the β adrenore-
ceptor antagonist propranolol led to suppression of cold-induced
thermogenesis in muscle (presumably β2 AR mediated) but did
not alter cold-induced thermogenesis in BAT (presumably β3
mediated; Wijers et al., 2011).
Additionally, the pre-treatment with diazepam – a common
practice meant to suppress FDG uptake of BAT during PET scan-
ning – did not result in reduced BAT activity in a randomized
controlled trial (Sturkenboom et al., 2009).
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PHARMACOLOGICAL TARGETING OF THERMOGENESIS AND
BAT
A calculation performed on the basis of glucose uptake and esti-
mated usage of fatty acids in BAT of healthy individuals yielded
the result that full activation of the present BAT would lead to a
potential consumption of 4.1 kg of adipose tissue over the course
of a year (Virtanen et al., 2009). Increasing thermogenesis phar-
macologically could therefore provide a promising approach to
prevent weight gain and facilitate weight loss in humans.
PHARMACOLOGIC ACTIVATION OF THERMOGENESIS
About eight decades ago 2,4-dinitrophenol (DNP), an artiﬁcial
uncoupler of mitochondrial respiration,was used to induceweight
loss in humans. It is a small lipophilic molecule that acts as a
protonophore, as it can carry protons across membranes (Berg
et al., 2007).
The substance was introduced as a drug for weight reduction
in the 1930s and a series of studies demonstrated it to cause
increased metabolic rate and considerable weight loss without
dietary restriction. Since nitrogen excretion remained stable upon
treatment with DNP, it was assumed that weight loss was due to fat
loss and that muscle was spared. The efﬁcacy of the substance led
to a widespread use even as non-prescription drug. Due to the nar-
row therapeutic range of DNP several cases of fatal hyperthermia
occurred, but given the large number of patients who had taken it
(more than 100,000 by 1934), the number of severe adverse events
was remarkably low. In 1935 several cases of cataract were reported
in women taking DNP, which ﬁnally resulted in its withdrawal
from the market in 1938 (Harper et al., 2001). DNP does of course
not selectively uncouple BAT mitochondria, but it nevertheless
provides an important proof of principle, as it demonstrates the
efﬁcacy of mitochondrial uncoupling for weight loss in humans.
Central stimulation of BAT via the SNS is believed to contribute
to the weight reducing effect of sibutramine (Liu et al., 2002). A
popular “herbal” weight loss drug, ephedrine, also increases SNS
activity and activates BAT, thereby increasing oxygen consump-
tion and thermogenesis (Dulloo et al., 1991; Baba et al., 2007). Yet,
stimulation of the SNS can lead to adverse effects such as tachy-
cardia, hypertension, and cardiac arrhythmias, all of which are
highly undesirable, especially in obese patients already suffering
from cardiovascular disease.
A more selective activation of BAT could be achieved through
β3-AR agonists. In fact, this strategy has been shown to be effec-
tive in rodents (Nagase et al., 1996; Ghorbani and Himms-Hagen,
1997; Umekawa et al., 1997). The orally available selective β3-
AR agonist L-796568 acutely increased energy expenditure and
lipolysis in obese men (Van Baak et al., 2002), but no effects on
thermogenesis or body fat were observed after extended treatment
over 28 days, probably due to β3-AR down-regulation (tachy-
phylaxis; Larsen et al., 2002). Another study in young, lean men
demonstrated increased insulin sensitivity and fat oxidation after
8 weeks of treatment with the β3-AR agonist CL316,243, while
24 h-energy expenditure and body weight after 8 weeks remained
unchanged as compared to baseline (Weyer et al., 1998).
It must be noted that these studies measured energy expendi-
ture to assess the activation of adaptive thermogenesis. Using FDG
PET–CT to visualize BAT activity could possibly detect smaller
changes induced by β3-AR agonists and should therefore be used
for future trials testing similar compounds.
The thermogenic effect of thyroid hormones is well known.
Not surprisingly levothyroxine and triiodothyronine have been
used to facilitate weight loss in obese patients. Unfortunately,
administration of excess thyroid hormone results in overt hyper-
thyroidism, a condition associated with increased BMR, tachy-
cardia, atrial arrhythmia, muscle wasting, and osteoporosis. The
CNS effects of excess thyroid hormone include increased irritabil-
ity, nervousness, and anxiety (Baxter and Webb, 2009). However,
the effects of thyroid hormones are mediated by different iso-
forms of the THR in a tissue speciﬁc fashion. THRα conveys
most of the effects on bone development, cardiac gene expres-
sion, heart rate, and catecholamine potentiation, while activation
of THRβ1 in mice increased UCP1 expression in BAT (Melmed
and Conn, 2005; Ribeiro et al., 2010). Accordingly, the thyroid hor-
mone mimetics GC-1 and KB141, which are selective for THRβ1,
reduced diet induced obesity and normalized serum lipids via
increased metabolic rate while not affecting heart rate (Grover
et al., 2003, 2004; Villicev et al., 2007). In diabetic ob/ob mice
KB141 improved glucose tolerance and insulin sensitivity (Bryz-
galova et al., 2008). Thus selective thyroid hormone mimetics
might also be of therapeutic beneﬁt in humans.
Activation of the G-protein coupled receptor TGR5 by bile
acids increased the expression of DIO2 in BAT and resulted in
increased energy expenditure and reduced body weight in mice
(Watanabe et al., 2006). Stimulation of DIO2 expression in BAT is
particularly interesting as this approach increases triiodothyronine
availability locally but not systemically thus obviating the delete-
rious effects of hyperthyroidism. The co-expression of TGR5 and
DIO2 in BAT makes bile acids and derived compounds promising
drug candidates for the activation of thermogenesis.
EXPANSION OF BROWN ADIPOSE TISSUE
As outlined above, the prevalence of active BAT, as determined
by FDG PET–CT, is lower in overweight and obese subjects than
in lean controls. To make use of the energy dissipating effect of
BAT in obese persons, it might thus be necessary to expand the
amount of BAT. Recently, brown adipocyte progenitors that could
be differentiated into UCP1 expressing cells in vitro have been
discovered in human WAT (Elabd et al., 2009). Additionally, Lee
et al. obtained fat biopsies from the supraclavicular fossa guided
by PET–CT. They were able to differentiate brown adipocyte pre-
cursors to UCP1 expressing brown adipocytes, regardless whether
PET analysis had shown active BATor not (Lee et al., 2011a). These
ﬁndings provide a rationale for therapeutic expansion of BAT in
humans.
In rodents several small molecules and hormones have been
found to promote the expansion of BAT. Fibroblast growth fac-
tors (FGF) are a family of polypeptide growth factors that regulate
cell proliferation,migration, anddifferentiationduring embryonic
development and function as homeostatic factors in tissue repair
and response to injury in the adult organism (Ornitz and Itoh,
2001). Several members of the family have been implied in BAT
physiology.
Cold exposure induces the expression of basic ﬁbroblast growth
factor (bFGF= FGF-2) in BAT and this growth factor seems to
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stimulate BAT growth through autocrine feedback (Yamashita
et al., 1994; Asano et al., 1999).
While FGF-16 mainly seems to be responsible for growth of
BAT during embryonic development (Konishi et al., 2000), FGF-
19 and FGF-21 demonstrated effects on thermogenesis in adult
mice. Intra-cerebroventricular administration of FGF-19 in mice
increased metabolic rate, prevented diet induced obesity and
improved insulin sensitivity (Fu et al., 2004). It is an especially
attractive molecule since it speciﬁcally binds to FGF-receptor 4
and does not appear to be mitogenic.
In newborn mice FGF-21 expression in the liver is reduced in
response to fasting and induced by suckling via PPARα depen-
dent mechanisms. Injection of FGF-21 into newborn fasting mice
induced genes involved in thermogenesis in BAT and increased
body temperature. In vitro FGF-21 induced expression of thermo-
genic genes and increased total and uncoupled respiration (Hon-
dares et al., 2010). Interestingly, FGF-21 expression is induced
in BAT itself by cold exposure or adrenergic stimulation via β-
adrenergic pathways (Chartoumpekis et al., 2011; Hondares et al.,
2011).
Fibroblast growth factors are attractive from a pharmacological
point of view: like other peptides they might be produced recom-
binantly or substituted by small molecules that speciﬁcally activate
FGF receptors and could easily be produced in large scale.
BMP-7, a member of the TGF-β superfamily was originally
identiﬁed as a bone inducer, but recent evidence suggests an
important role in brown fat development as well. BMP-7 can acti-
vate the full program of brown fat differentiation both in vitro
and in vivo. Tseng et al. (2008) injected mice with hepatotropic
adenoviruses expressing BMP-7 resulting in hepatic overexpres-
sion and secretion of the protein. In comparison to control mice
those injected with the BMP-7 expressing retroviruses showed
increased thermogenesis, higher body temperature and reduced
body weight.
An alternative strategy could be to transdifferentiate adipocyte
precursors obtained from liposuction into brown adipocytes
ex vivo and then re-transplant the thermogenically active cells.
This could be achieved through overexpression of PRDM16,
FOXC2, or PGC-1α in the cells. Compared to a conventional
pharmacological approach, however, such a method would be
elaborate and expensive and questions of optimal location for
implantation, of blood supply and of innervation remain to be
solved.
Currently, FDG PET–CT is the sole imaging modality to inves-
tigate BAT activity directly. This is a major obstacle in the investi-
gation of BAT activity and potential pharmaceuticals that increase
BAT activity. Recent developments in nuclear magnetic resonance
imaging (MRI; Hu et al., 2010; Branca and Warren, 2011) could
facilitate the evaluation of BAT activity without exposure to ion-
izing radiation thus giving the research in the ﬁeld an enormous
boost.
Apart from the search for drugs that increase BAT thermogene-
sis, it will also be important to further investigate the consequences
of thermoneutrality and cold exposure. Humans in the developed
world spend most of their time in a thermoneutral zone main-
tained by advanced heating systems and protective clothing (Van
Marken Lichtenbelt and Schrauwen, 2011). As BAT is activated
by sensing cold long prior to a drop of core temperature and at
ambient temperatures around 16˚C,deliberately lowering ambient
temperatures in buildings could be a feasible approach to increase
BAT activity and to prevent obesity.
CONCLUSION
Given the growing world-wide prevalence and increasing burden
of obesity and associated diseases and the current lack of effective
treatment strategies, new therapeutic approaches in the ﬁeld of
anti-obesity therapies are clearly needed.
During the recent years our knowledge of BAT physiology
and development and its implications in metabolic disease has
increased dramatically. Most importantly, there is robust evidence
that BAT is present in a majority of human adults. Furthermore,
a growing body of literature indicates that active BAT is inversely
associated with obesity and metabolic disease. In rodent models
several pharmacological approaches which increase BAT activity,
have been proven to effectively prevent obesity, facilitate weight
reduction, and ameliorate insulin resistance. Deducing from the
animal model these approaches might work in humans as well.
Many questions regarding therapeutic activation or expan-
sion of BAT remain to be solved. It is yet unclear how effective
an increase of thermogenesis would be to reduce obesity and
ameliorate insulin resistance. Compensating mechanisms, such
as increased appetite, could reduce the beneﬁts of this approach.
Not least, the infamous history of the uncoupling agent DNP
reminds us to pay close attention to contingent risks of drugs that
activate thermogenesis. Considering the disappointing results of
pharmacological approaches targeting energy intake and appetite,
stimulation of BAT activity and increasing energy expenditure
would provide exciting new options in obesity therapy.
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